Overview

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Diclofenac
Ibuprofen
Lumiracoxib